RALGPS1

Across TCGA pan-cancer cohorts, RALGPS1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated RALGPS1 data layer compared with 21 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher RALGPS1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated RALGPS1 expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

OV, UCEC, and SARC are the cancer types where RALGPS1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	II,III,IV	0.018	0.846	<.001	48	view →
UCEC	DFS	Median	All	0.970	0.629	.010	14	view →
SARC	OS	Median	All	0.174	0.860	<.001	6	view →
SKCM	DFS	Median	All	0.192	0.757	.022	6	view →
STAD	OS	Median	III,IV	1.000	0.321	.019	5	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

RALGPS1–OV (OS)

Open the OV breakdown →